• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/6/25 7:05:27 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $EYPT alert in real time by email
    8-K
    false000131410200013141022025-08-062025-08-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 06, 2025

     

     

    EyePoint Pharmaceuticals, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    000-51122

    26-2774444

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    480 Pleasant Street

     

    Watertown, Massachusetts

     

    02472

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (617) 926-5000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.001

     

    EYPT

     

    The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On August 6, 2025, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit No.

    Description

    99.1

     

    Press Release of EyePoint Pharmaceuticals, Inc. dated August 6, 2025

    104

     

    Cover Page Interactive Data File (embedded within the inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    EYEPOINT PHARMACEUTICALS, INC.

     

     

     

     

    Date:

    August 6, 2025

    By:

    /s/ George O. Elston

     

     

     

    George O. Elston
    Executive Vice President and Chief Financial Officer

     


    Get the next $EYPT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYPT

    DatePrice TargetRatingAnalyst
    6/17/2025$28.00Outperform
    RBC Capital Mkts
    1/7/2025$33.00Buy
    Citigroup
    10/16/2024Sector Outperform
    Scotiabank
    8/28/2024$15.00Buy
    Jefferies
    1/22/2024$35.00Overweight
    JP Morgan
    11/2/2023$20.00Buy
    Mizuho
    4/21/2023$33.00Outperform
    Robert W. Baird
    7/7/2022$21.00Buy
    Chardan Capital Markets
    More analyst ratings

    $EYPT
    SEC Filings

    View All

    SEC Form S-8 filed by EyePoint Pharmaceuticals Inc.

    S-8 - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    8/7/25 4:31:23 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by EyePoint Pharmaceuticals Inc.

    10-Q - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    8/7/25 4:05:32 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - EyePoint Pharmaceuticals, Inc. (0001314102) (Filer)

    8/6/25 7:05:27 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 140,600 shares of EyePoint common stock to eight new employees. The stock options were granted on September 15, 2025. The grants were approved by the Compensation Committee and made

    9/16/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Announces Participation at Upcoming Investor Conferences

    WATERTOWN, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Citi's 2025 BioPharma Back to School ConferenceForum: Fireside ChatDate: Tuesday, September 2, 2025Time: 2:30 p.m. ET Cantor Global Healthcare ConferenceForum: Fireside ChatDate: Wednesday, September 3, 2025Time: 2:45 p.m. ETMorgan Stanley 23rd Annual Global Healthcare Conference Forum: 1x1 Investor MeetingsDate: Tuesday, September 9, 2025 A live webcast an

    8/26/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    WATERTOWN, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 18,000 shares of EyePoint common stock to two new employees. The stock options were granted on August 15, 2025. The grants were approved by the Compensation Committee and made as an ind

    8/18/25 4:01:00 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Elston George gifted 20,000 shares and received a gift of 20,000 shares, decreasing direct ownership by 24% to 62,114 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    9/22/25 4:11:05 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. converted options into 2,000 shares, increasing direct ownership by 5% to 38,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    7/11/25 4:07:01 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    President and CEO Duker Jay S. converted options into 16,667 shares and covered exercise/tax liability with 7,688 shares, increasing direct ownership by 911% to 9,965 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    7/11/25 4:06:49 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zaderej Karen L. bought $59,000 worth of shares (10,000 units at $5.90), increasing direct ownership by 38% to 36,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/19/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Zaderej Karen L. bought $54,450 worth of shares (10,000 units at $5.45), increasing direct ownership by 61% to 26,500 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    5/15/25 4:06:14 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Dicicco Wendy F bought $19,997 worth of shares (2,567 units at $7.79), increasing direct ownership by 35% to 9,967 units (SEC Form 4)

    4 - EyePoint Pharmaceuticals, Inc. (0001314102) (Issuer)

    8/21/24 4:32:51 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on EyePoint Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of EyePoint Pharmaceuticals with a rating of Outperform and set a new price target of $28.00

    6/17/25 7:49:38 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Citigroup initiated coverage on EyePoint Pharmaceuticals with a new price target

    Citigroup initiated coverage of EyePoint Pharmaceuticals with a rating of Buy and set a new price target of $33.00

    1/7/25 7:52:05 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Scotiabank initiated coverage on EyePoint Pharmaceuticals

    Scotiabank initiated coverage of EyePoint Pharmaceuticals with a rating of Sector Outperform

    10/16/24 8:38:45 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Leadership Updates

    Live Leadership Updates

    View All

    EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

    WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Reginald J. Sanders, M.D., FASRS, a distinguished leader in ophthalmology, to its Board of Directors. "I am pleased to welcome Dr. Sanders to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint. "Scientific and medical leadership underpin our mission to develop innovative therapeutics for patients with serious retinal diseases, and as a prominent leader in the retina community, Dr. San

    1/8/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors

    WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. "I am honored to welcome Fred Hassan to EyePoint's Board," said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. "He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future

    9/4/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

    - Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board – - Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O, F.A.R.V.O join in advance of global Phase 3 clinical trials for EYP-1901(DURAVYU) in wet AMD – - Company on track to initiate the first Phase 3 pivotal trial (LUGANO) for DURYVU in wet AMD in 2H 2024 - WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists

    4/2/24 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Financials

    Live finance-specific insights

    View All

    EyePoint Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Completed Phase 3 enrollment for DURAVYU™ in wet AMD with over 800 patients enrolled and randomized – – LUGANO and LUCIA trials each rapidly enrolled in seven months underscoring strong physician and patient interest – – Topline 56-week data for LUGANO on track for readout in mid-2026 with LUCIA topline data to closely follow – – Northbridge, MA commercial manufacturing facility on line with DURAVYU registration batches underway – – $256 million of cash, cash equivalents and marketable securities as of June 30, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials – WATERTOWN, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuti

    8/6/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint to Report Second Quarter 2025 Financial Results on August 6, 2025

    WATERTOWN, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and highlight recent corporate developments. To access the live conference call, please register using the audio conference link: https://register-conf.media-server.com/register/BI2f02d8b4966b40da83f2ef4135b2ba78. A live audio webcast of the event can be accessed via the Investors section of the

    7/30/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments

    – Enrollment continues to exceed expectations in DURAVYU™ Phase 3 wet AMD clinical trials with over 90% of patients randomized into the LUGANO trial and over 50% into the LUCIA trial, reinforcing confidence in enrollment completion in 2H 2025 and expected first-to-market advantage – – $318 million of cash, cash equivalents and marketable securities as of March 31, 2025, provides cash runway into 2027, beyond topline data for both Phase 3 wet AMD trials expected in 2026 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious

    5/7/25 7:00:00 AM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EYPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 3:10:08 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/14/24 1:22:34 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by EyePoint Pharmaceuticals Inc.

    SC 13G/A - EyePoint Pharmaceuticals, Inc. (0001314102) (Subject)

    11/12/24 2:31:58 PM ET
    $EYPT
    Biotechnology: Laboratory Analytical Instruments
    Industrials